The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
Sharp increase in diabetes, hypertension and fatty liver in 30–50 age group
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
Analysis of over 93 lakh preventive health checkups reveals disease risks emerging as early as the 20s
Health of the Nation 2026, based on over 3 million assessments, finds rising diabetes, obesity, and hidden cardiac risks in under-30s and working professionals
The last-mile healthcare delivery across 1,100 villages, with focus on maternal health, diagnostics, and chronic disease management
Subscribe To Our Newsletter & Stay Updated
